The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Psychedelics and the Human Receptorome
Open accessAbstract
We currently understand the mental effects of psychedelics to be caused by agonism or partial agonism of 5-HT(2A) (and possibly 5-HT(2C)) receptors, and we understand that psychedelic drugs, especially phenylalkylamines, are fairly selective for these two receptors. This manuscript is a reference work on the receptor affinity pharmacology of psychedelic drugs. New data is presented on the affinity of twenty-five psychedelic drugs at fifty-one receptors, transporters, and ion channels, assayed by the National Institute of Mental Health-Psychoactive Drug Screening Program (NIMH-PDSP). In addition, comparable data gathered from the literature on ten additional drugs is also presented (mostly assayed by the NIMH-PDSP). A new method is introduced for normalizing affinity (K(i)) data that factors out potency so that the multi-receptor affinity profiles of different drugs can be directly compared and contrasted. The method is then used to compare the thirty-five drugs in graphical and tabular form. It is shown that psychedelic drugs, especially phenylalkylamines, are not as selective as generally believed, interacting with forty-two of forty-nine broadly assayed sites. The thirty-five drugs of the study have very diverse patterns of interaction with different classes of receptors, emphasizing eighteen different receptors. This diversity of receptor interaction may underlie the qualitative diversity of these drugs. It should be possible to use this diverse set of drugs as probes into the roles played by the various receptor systems in the human mind.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HANDBOOK OF EXPERIMENTAL PHARMACOLOGY
Reichlin, S. (1969) · The American Journal of The Medical Sciences · doi:10.1097/00000441-196911000-00008 · Cited by 1,134
Nichols, D. E., & Nichols, C. D. (2008) · Chemical Reviews · doi:10.1021/cr078224o · Cited by 895 · cited 1×
“5-HT6 and 5-HT7 are grouped because they share a common G-protein, Gs [13].”
BackgroundSalvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist
Roth, B. L., Baner, K., Westkaemper, R., Siebert, D., Rice, K. C., Steinberg, S., Ernsberger, P., & Rothman, R. B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182234399 · Cited by 784
Neubig, R. R., Spedding, M., Kenakin, T., & Christopoulos, A. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.4 · Cited by 665
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & McKenney, J. D. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 631
Nichols, D. E. (1986) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1986.10472362 · Cited by 563
Classification of multiple morphine and enkephalin binding sites in the central nervous system.
Wolozin, B. L., & Pasternak, G. W. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.10.6181 · Cited by 372
Cloning and Pharmacological Characterization of the Rat CB2 Cannabinoid Receptor
Griffin, G., Tao, Q., & Abood, M. E. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35367-4 · Cited by 207
Iwamura, H., Suzuki, H., Ueda, Y., Kaya, T., & Inaba, T. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38760-9 · Cited by 200
Largent, B. L., Gundlach, A. L., & Snyder, S. H. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.15.4983 · Cited by 196
Glennon, R. A., Young, R., & Rosecrans, J. A. (1983) · European Journal of Pharmacology · doi:10.1016/0014-2999(83)90464-8 · Cited by 190 · cited 1×
“. This understanding was first developed in the 1980s”
BackgroundInternational Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification.
Vanhoutte, P. M., Barnard, E. A., Cosmides, G. J., Humphrey, P. P., Spedding, M., & Godfraind, T. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06779-1 · Cited by 188
Synthesis and in vitro opioid activity profiles of DALDA analogues
Schiller, P. W., Nguyen, T. M.-D., Berezowska, I., Dupuis, S., Weltrowska, G., Chung, N. N., & Lemieux, C. (2000) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(00)01171-5 · Cited by 161
2-Substituted Tryptamines: Agents with Selectivity for 5-HT6Serotonin Receptors
Glennon, R. A., Lee, M., Rangisetty, J. B., Dukat, M., Roth, B. L., Savage, J. E., McBride, A., Rauser, L., Hufeisen, S., & Lee, D. K. H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990550b · Cited by 149
Do classical hallucinogens act as 5-HT2 agonists or antagonists?
Glennon, R. A. (1990) · PubMed · Cited by 136
Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines
Blair, J. B., Kurrasch-Orbaugh, D., Marona-Lewicka, D., Cumbay, M. G., Watts, V. J., Barker, E. L., & Nichols, D. E. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000339w · Cited by 131
Activity of opioid ligands in cells expressing cloned mu opioid receptors
Gharagozlou, P., DeMirci, H., Clark, J. D., & Lameh, J. (2003) · BMC Pharmacology · doi:10.1186/1471-2210-3-1 · Cited by 106
Mauler, F., Mittendorf, J., Horváth, E., & Vry, J. D. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.302.1.359 · Cited by 99
Nichols, D. E., Frescas, S. P., Marona‐Lewicka, D., & Kurrasch‐Orbaugh, D. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020153s · Cited by 91
Glennon, R. A., Darmani, N. A., & Martin, B. R. (1991) · Life Sciences · doi:10.1016/0024-3205(91)90603-9 · Cited by 76
Opiate binding in calf thalamic membranes: a selective mu 1 binding assay.
Clark, J. A., Houghten, R. A., & Pasternak, G. W. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09750-0 · Cited by 69
Serotonin receptors and their ligands: A lack of selective agents
Glennon, R. A., & Dukat, M. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90121-h · Cited by 68
Zhao, G., Qian, X., Schiller, P. W., & Szeto, H. H. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.054775 · Cited by 65
De Vry, J., Denzer, D., Reissmueller, E., Eijckenboom, M., Heil, M., Meier, H., & Mauler, F. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.062836 · Cited by 63
Glennon, R. A., Titeler, M., & Young, R. (1986) · PubMed · Cited by 57
Standifer, K. M., Cheng, J., Brooks, A. I., et al. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22533-2 · Cited by 51
Darmani, N. A., Mock, O. B., Towns, L. C., & Gerdes, C. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90542-8 · Cited by 38
Whiteside, G. T., Harrison, J. E., Pearson, M. S., Chen, Z., Rotshteyn, Y., Turchin, P. I., Pomonis, J. D., Mark, L., Walker, K. M., & Brogle, K. C. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.063560 · Cited by 26
Binding characteristics of [3H]14‐methoxymetopon, a high affinity µ‐opioid receptor agonist
Spetea, M., Tóth, F., Schütz, J., Ötvös, F., Tóth, G., Benyhe, S., Borsodi, A. D., & Schmidhammer, H. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02744.x · Cited by 21
Further evidence for enigmas in adaptation mechanisms for the DOI-induced behaviors
Darmani, N. A. (1992) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(92)90406-6 · Cited by 9
Cited by
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649
Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.001 · Cited by 379
Metadata
- Authors
- Ray, T. S.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-02-02
- Volume
- 5
- Issue
- 2
- Pages
- e9019
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2166952073
- Cited by
- 301
- References
- 30
- FWCI
- 8.13
- Type
- journal article
- Language
- en
- Update notices
- correction (2010-03-04)
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.